SCHEMBL633864

SCHEMBL633864

COc1cc(N2C(=O)N(CCCCCN3C(=O)N(c4ccc([N+](=O)[O-])c(OC)c4)C(=O)C3(C)C)C(C)(C)C2=O)ccc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.48
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
AR P10275 3/20 0.42
PGR P06401 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
NFKB1 P19838 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633631 0.85 SMN1; SMN2 (0.49) LMNAARPGRSMN1; SMN2MEN1
SCHEMBL634305 0.84 PGR (0.44) LMNAARPGRSMN1; SMN2MEN1
SCHEMBL634148 0.81 AR (0.62) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL633848 0.81 AR (0.62) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL633318 0.81 AR (0.62) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL629028 0.81 SMN1; SMN2 (0.45) LMNAARPGRSMN1; SMN2MEN1
SCHEMBL633883 0.80 AR (0.64) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL4029756 0.78 AR (0.58) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL634846 0.78 AR (0.64) SIRT6LMNAARPGRSMN1; SMN2
SCHEMBL629374 0.77 AR (0.57) SIRT6LMNAARPGRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419422-B1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA SAS (FR) 2014-10-15 EP disclosed
US-8624037-B2 Imidazolidine-2,4-dione derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2014-01-07 US disclosed
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-04-19 US disclosed
EP-2419422-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-02-22 EP disclosed
WO-2010119194-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT MKI67, CCNI, CCNA1 SIRT6 4236/4885ALDH1A1 558/4885LMNA 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.